Abstract
Lay Summary We observed efficacy and safety of ustekinumab in very early-onset inflammatory bowel disease, which has not been previously reported. Clinical remission at 52% was 75%, often persisting beyond 2 years. Further studies including larger numbers of cases are needed to confirm this observation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have